Can we still learn from single center experience after PARTNER?

Benoit Daneault, Tamas Z Fulop, Paul Farand

Benoit Daneault, Tamas Z Fulop, Paul Farand, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

Author contributions: Daneault B wrote the manuscript; Fulop TZ collected the materials; Farand P supervised the publication of this commentary.

Correspondence to: Paul Farand, MD, MSc, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada. paul.farand@usherbrooke.ca

Telephone: +1-819-3461110 Fax: +1-819-8206806
Received: October 8, 2012 Revised: January 13, 2013 Accepted: February 5, 2013 Published online: March 26, 2013

Abstract

With the publication of the Placement of Aortic Transcatheter Valves (PARTNER) trial, transcatheter aortic valve replacement (TAVR) has undoubtedly become the gold standard for severe aortic stenosis in patients that are not suitable candidate for surgical aortic valve replacement (AVR). The PARTNER trial also showed that TAVR is non-inferior to AVR in high-risk patients. A recent publication by Ben-Dor et al reviewed 900 patients who were referred for TAVR evaluation (PARTNER trial) between April 2007 and May 2011. These patients had severe AS defined by a mean gradient $\geq 40$ mmHg or valvular area $< 1$ cm$^2$. Only 13% ($n = 19$) of AVR and 4.9% ($n = 29$)

COMMENTARY ON HOT TOPICS

We have read with great interest the recent manuscript by Ben-Dor et al evaluating the outcome of high-risk patients with severe aortic stenosis (AS) referred to their institution for a trial of transcatheter aortic valve replacement (TAVR) stratified by the treatment they received, and believe it is worth discussion. Symptomatic severe AS is a deadly and incapacitating disease when left untreated. For many decades, surgical aortic valve replacement (AVR) has been considered the treatment of choice because of its ability to improve survival and symptoms. It was however shown that approximately one third of patients with severe symptomatic AS do not benefit from AVR because of multiple of reasons. Balloon aortic valvuloplasty (BAV), although less invasive than AVR is only palliative. More recently, TAVR has been shown to be superior to medical therapy (including BAV) in patients that are not candidates for AVR and to be non-inferior to AVR in high-risk patients.

Ben-Dor et al reviewed 900 patients who were referred for TAVR evaluation (PARTNER trial) between April 2007 and May 2011. These patients had severe AS defined by a mean gradient $\geq 40$ mmHg or valvular area $< 1$ cm$^2$. Only 13% ($n = 19$) of AVR and 4.9% ($n = 29$)
of medially treated patients were enrolled in the PARTNER trial. The PARTNER trial as been described in detail[1] but in summary consisted of two parallel studies. The cohort A consisted of patients at high-risk for AVR (risk of 30-d mortality ≥ 15%) that were randomized to TAVR (from a trans-femoral or trans-apical approach) or AVR. The cohort B included patients that were deemed non-operative based on an estimated risk of mortality or major irreversible morbidity of ≥ 50%; which were randomized to TAVR vs medical therapy (including possible BAV). Ben-Dor et al[2] evaluated the outcomes of patients treated in their institution stratified by the treatment they received. Medical treatment was adopted in 66.1% of patients (n = 595), among whom 345 patients also had BAV, 17.6% (n = 159) had TAVR and 16.3% (n = 146) had AVR. Groups were significantly different in their baseline characteristics with younger and healthier patients undergoing AVR and sicker patients with lower ejection fraction and higher BNP value in the medical treatment group. The STS score was significantly different across groups with values of 8.5%, 11.8% and 12.1% for AVR, TAVR and medical treatment respectively (P < 0.001). The transcatheter heart valve (THV) used for TAVR was the Edwards SAPIEN THV (Edwards Life Sciences, Irvine, CA, United States). A trans-femoral (TF) approach was used in 69.1% (n = 110) of cases and a trans-apical (TA) approach in 30.9% (n = 49).

In their study, Ben-Dor et al found a 1-year mortality of 21.2%, 21.3% and 36.4% for patients treated with TAVR, AVR and medical therapy respectively (P < 0.001). In the medical therapy group, patient who had a BAV performed had higher mortality (55% vs 34%, P < 0.01). Thirty-day mortality was 11.7%, 12.8% and 10.1% for TAVR, AVR and medical therapy respectively. The STS score predicted 30-d mortality was 11.8%, 8.4% and 12.3% while the logistic Euroscore predicted 41.2%, 34% and 43.1% for TAVR, AVR and medical therapy respectively (risk of 30-d mortality ≥ 0.01). The transcatheter approach in 30.9% (n = 49).

In their study, Ben-Dor et al found a 1-year mortality of 21.2%, 21.3% and 36.4% for patients treated with TAVR, AVR and medical therapy respectively (P < 0.001). In the medical therapy group, patient who had a BAV performed had higher mortality (55% vs 34%, P < 0.01). Thirty-day mortality was 11.7%, 12.8% and 10.1% for TAVR, AVR and medical therapy respectively. The STS score predicted 30-d mortality was 11.8%, 8.4% and 12.3% while the logistic Euroscore predicted 41.2%, 25.6% and 43.1% for TAVR, AVR and medical therapy respectively. Patients with STS score > 15 had a significantly greater mortality (59.2%) compared with those with STS score < 15 (35.2%). In the entire cohort, atrial fibrillation and renal failure were found to be independent predictor of mortality. When stratified by the treatment received, independent predictor of mortality were STS score and renal failure for patients undergoing TAVR, renal failure and NYHA class IV for patients undergoing AVR and renal failure, pulmonary artery pressure and aortic systolic pressure for patient treated medically.

This is a retrospective, non-randomized single center study evaluating outcomes of patients referred for TAVR, stratified by the treatment received. Multiple limitations from the trial should be discussed. Because of the absence of randomization, the 3 groups compared in this study represent very different populations. The medical therapy group consisted mainly of patients that were not randomized in the PARTNER trial, most likely representing patients that are just too sick to benefit from TAVR (often referred has the cohort C patients). In fact, 30-d mortality was higher (10.1%) in these patients compared to the medically treated patients from the PARTNER trial (2.8%). What is surprising is that the 1-year mortality of medically treated patients in this study is lower (36.4%) then the 49.7% observed in PARTNER. These findings are hard to explain and should raise questions about the clinical follow-up of this study, which is not detailed in the manuscript. An alternative is that some patients received medical therapy because they had asymptomatic aortic stenosis, hence no indication for valve replacement. TAVR and AVR patients were also different. Non-operative patients received TAVR and lower risk patients that would not qualify for the PARTNER trial based on their risk were included in the AVR group. Despite these differences, the 1-year mortality was similar between both groups. Interestingly, the STS predicted 30-d mortality for AVR was lower than what was observed, a finding that is in contradiction with the observations from the PARTNER trial. TAVR patients, despite all being part of the PARTNER trial had a 30-d mortality (11.7%) that was worse than in the trial (5.0% for non-operative and 3.4% for high-risk patients). Given the absence of randomization between the AVR and TAVR groups in this study, it would be unadvisable to conclude to the equivalence of these two approach solely based on this study. In a recent meta-analysis of 16 TAVR studies using VARC criteria and regrouping 3519 patients[3], the 1-year mortality was 22.1%, similar to what observed by Ben-Dor et al[2]. Significant outcomes such as vascular complications, stroke, acute kidney injury are absent from this present trial and could put some light on the early mortality.

Medically treated patients are driving the results of their multivariable analysis. Also, their multivariable analysis for TAVR and AVR patients are over fitted in relation to the number of events. Renal failure was found to be a predictor of mortality for all patients and is consistent with the current literature[4,5]. They however did not define was they considered as renal failure and did not report on acute kidney injury which has been described as an independent predictor of mortality after TAVR and AVR[5]. The proportion of patient on dialysis was also not reported in this study. The PARTNER trial excluded patients on chronic dialysis and patients with a serum creatinine ≥ 3 mg/dL. It would have been interesting to know the proportion of these patients represented in the AVR and in the medically treated groups. No data on frailty was presented in this study. Frailty is known to be an independent predictor of mortality after open-heart surgeries[6], is often a cause of non-operability and has now been characterize in the VARC-2 consensus document[7]. Frailty could be an unmeasured confounder that could alter the results of this multivariable analysis.

In conclusion, this single center, non-randomized study is globally consistent with the PARTNER trial[4,5] and larger multicenter registries[8-14]. TAVR is already recognized as the gold standard therapy for non-operative patients that cannot benefit from aortic valve replacement. The biggest challenge remaining will be to identify
patients that are dying with severe AS and not from AS and that would not improve after TAVR. New trials (PARTNER 2, SURTAVI) are already randomizing moderate-risk patients to AVR vs TAVR, searching for potential benefits of TAVR in these patients.

REFERENCES

1. Ben-Dor I, Dvir D, Barbash IM, Okubagzi P, Torguson R, Xu Z, Lindsay J, Satler LF, Pichard AD, Waksman R. Outcomes of patients with severe aortic stenosis at high surgical risk evaluated in a trial of transcatheter aortic valve implantation. *Am J Cardiol* 2012; 110: 1008-1014 [PMID: 22721576 DOI: 10.1016/j.amjcard.2012.05.034]

2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeers F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 2003; 24: 1231-1243 [PMID: 12838181 DOI: 10.1016/S0195-668X(03)00201-X]

3. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Peterson JL, Akin JJ, Anderson WN, Wang D, Pocock S. Transcatheter aortic valve-implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010; 363: 1597-1607 [PMID: 20961243 DOI: 10.1056/NEJMoa1008232]

4. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babalaros V, Thoumani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011; 364: 2187-2198 [PMID: 21639811 DOI: 10.1056/NEJMoa1103510]

5. Généreux P, Head SJ, Van Mieghem NM, Kodali S, Kirtane AJ, Xu K, Smith C, Serruys PW, Kappetein AP, Leon MB. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. *J Am Coll Cardiol* 2012; 59: 2317-2326 [PMID: 22503058 DOI: 10.1016/j.jacc.2012.02.022]

6. Lassenig A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. *J Am Soc Nephrol* 2004; 15: 1597-1605 [PMID: 15153571 DOI: 10.1097/01.FAS.0000130340.93900.DD]

7. Sinning JM, Chanen A, Steinbühler H, Adenauner V, Hammerstingl C, Nickenig G, Werner N. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2010; 3: 1141-1149 [PMID: 20887750 DOI: 10.1016/j.jcin.2010.09.009]

8. Bagur R, Webb JG, Nieltschp F, Dumont E, De Laro-chellière R, Doyle D, Masson JB, Gutiérrez MJ, Clavel MA, Bertrand OF, Pibarat P, Rodés-Cabau J. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. *Eur Heart J* 2010; 31: 865-874 [PMID: 20035180 DOI: 10.1093/eurheartj/ehq552]

9. Afilalo J, Eisenberg MJ, Morin JF, Bergman H, Monette J, Noisexe N, Perrault LP, Alexander KP, Langlois Y, Dendu-kuri N, Chamoun P, Kasparian G, Robichaud S, Gharacholi SM, Boivin JF. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. *J Am Coll Cardiol* 2010; 56: 1668-1676 [PMID: 21050978 DOI: 10.1016/j.jacc.2010.06.039]

10. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cudlip DE, van ES GA, Hahn RT, Kirtane AJ, Kruffco MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckxs P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *J Am Coll Cardiol* 2010; 56: 1438-1454 [PMID: 20866686 DOI: 10.1016/j.jacc.2010.02.041]

11. Gild M, Ettlichaniöff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Legeruier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetche D, Carrie D, Albat B, Cribier A, Rioufoul G, Sudre A, Blanchard D, Collet F, Dos Santos P, Meneveau N, Tioufanvazian A, Causin C, Guyon P, Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favreau X, Ohlimann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Van Belle E, Laskar M. Registry of transcatheter aortic valve implantation in high-risk patients. *N Engl J Med* 2012; 366: 1705-1715 [PMID: 22551129 DOI: 10.1056/NEJMoa1114705]

12. Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Feindel CM, Osten M, Natarajan MK, Velianou JL, Martucci G, Devarennes B, Chisholm R, Peterson MD, Lichtenstein SV, Nieltschp F, Doyle D, DeLarochellière R, Tesh K, Chu V, Dancea A, Lachapelle K, Cheema A, Latter D, Horlick E. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol* 2010; 55: 1080-1090 [PMID: 20955533 DOI: 10.1016/j.jacc.2009.12.014]

13. Moat NE, Ludman P, de Belder MA, Bridgewater C, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach J, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Belle E, Laskar M. Registry of transcatheter aortic-valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. *J Am Coll Cardiol* 2011; 58: 2130-2138 [PMID: 22019110 DOI: 10.1016/j.jacc.2011.08.050]

14. Généreux P, Head SJ, Wood DA, Kodali SK, Williams MR, Paradis JM, Spaziano M, Kappetein AP, Webb JG, Cribier A, Leon MB. Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. *Eur Heart J* 2012; 33: 2386-2398 [PMID: 22851654 DOI: 10.1093/europamic/sjs280]